Publications - Page 47 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Fibrose pulmonaire - FPI
Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis

Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H.

Eur J Cancer. 2021 Mar;145:179-182.
Fibrose pulmonaire - FPI
Regulation of immune cells in lung fibrosis: the reign of regnase-1 ?

Froidure A, Crestani B.

Eur Respir J. 2021 Mar 11;57(3):2004029.
Fibrose pulmonaire - FPI
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Justet A, Klay D, Porcher R, Cottin V, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, Froidure A, Jouneau S, Wemeau L, Andrejak C, Gondouin A, Hirschi S, Blanchard E, Bondue B, Bonniaud P, Tromeur C, Prévot G, Marchand-Adam S, Funke-Chambour M, Gamez AS, Ba I, Papiris S, Grutters J, Crestani B, van Moorsel C, Kannengiesser C, Borie R; OrphaLung Network.

Eur Respir J. 2021 Feb 11;57(2):2003198.
Fibrose pulmonaire - FPI
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H; EXAFIP investigators and the OrphaLung network.

Lancet Respir Med. 2021 Sep 7: S2213-2600(21)00354-4.
Fibrose pulmonaire - FPI
IC4 : a new combined predictive index of mortality in idiopathic pulmonary fibrosis

Zinellu A, Collu C, Zinellu E, Ahmad K, Nasser M, Traclet J, Sotgiu E, Mellino S, Mangoni AA, Carru C, Pirina P, Cottin V, Fois AG.

Panminerva Med. 2021 Jan 26.
Hypertension pulmonaire (HTP)
Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy

Lechartier B, Berrebeh N, Huertas A, Humbert M, Guignabert C, Tu L.

Chest. 2022 Jan;161(1):219-231.
Fibrose pulmonaire - FPI
NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis

Louzada RA, Corre R, Ameziane El Hassani R, Meziani L, Jaillet M, Cazes A, Crestani B, Deutsch E, Dupuy C.

Eur Respir J. 2021 Jan 14;57(1):1901949.
Hypertension pulmonaire (HTP)
Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension

Gazengel P, Hascoët S, Amsallem M, Savale L, Montani D, Mercier O, Humbert M, Fadel E, Le Pavec J.

Eur Respir J. 2022 Jan 20;59(1):2102388.
Hypertension pulmonaire (HTP)
Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood

Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D, Mascarenhas TS, Errington N, Thompson AAR, Romanoski CE, Rischard F, Garcia JGN, Yuan JX, An TS, Desai AA, Coghlan G, Lordan J, Corris PA, Howard LS, Condliffe R, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort S, Gräf S, Morrell NW, Wilkins MR, Lawrie A, Wang D; UK National PAH Cohort Study Consortium.

Nat Commun. 2021 Dec 7;12(1):7104.
Hypertension pulmonaire (HTP)
Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI)

Cottin V, Bensimon L, Raguideau F, Chaize G, Hakmé A, Levy-Bachelot L, Vainchtock A, Dallongeville J, Bouvaist H, Brenot P.

PLoS One. 2021 Dec 7;16(12):e0260483.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis

Regulation of immune cells in lung fibrosis: the reign of regnase-1 ?

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

IC4 : a new combined predictive index of mortality in idiopathic pulmonary fibrosis

Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy

NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis

Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood

Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI)